GWS
SNDX icon

Glassman Wealth Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Glassman Wealth Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-99
Closed -$2.14K – 1561
2023
Q4 		$2.14K Buy
99
+61
+161% +$938 ﹤0.01% 1331
2023
Q3 		$552 Buy
+38
New +$719 ﹤0.01% 1711

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Glassman Wealth Services's SNDX Position: Q1 2024 in Review

Glassman Wealth Services sold out of Syndax Pharmaceuticals (SNDX) in Q1 2024, closing a stake of 99 shares — an estimated $2.14K sold.

Glassman Wealth Services first reported a position in SNDX in Q3 2023 and held it in 2 quarters. The position peaked at $2.14K in Q4 2023. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

  • Glassman Wealth Services reported no remaining Syndax Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 99 Syndax Pharmaceuticals shares in Q1 2024, an estimated $2.14K.
  • Glassman Wealth Services first reported a position in Syndax Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Glassman Wealth Services's Syndax Pharmaceuticals position peaked at $2.14K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.